TRILLIO, a porTable pRescription assistant Improving heaLth of Europeans citizens by increasing therapeutic adherence in eLderly people and in patIents affected by chrOnic diseases

Projektinformationen

TRILLIO

ID Finanzhilfevereinbarung: 816495

DOI

10.3030/816495

Projekt abgeschlossen

EK-Unterschriftsdatum 9 Mai 2018

Startdatum 1 Mai 2018

Enddatum 31 Oktober 2018

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

LA COMANDA SRL
Italy

Periodic Reporting for period 1 - TRILLIO (TRILLIO, a porTable pRescription assistant Improving heaLth of Europeans citizens by increasing therapeutic adherence in eLderly people and in patIents affected by chrOnic diseases)

Berichtszeitraum: 2018-05-01 bis 2018-10-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

"Therapeutic adherence is defined as “the extent to which a person’s behaviour – taking medication, following a diet, and/or executing lifestyle change - corresponds with agreed recommendations from a health care provider”. It is estimated that each year the poor adherence to medical treatments in Europe causes about 200,000 deaths and burdens on health expenditure up to 80 billion euro a year (AIFA source).
TRILLIO wants to improve health of Europeans citizens by increasing therapeutic adherence in elderly people and in patient affected by chronic diseases.
TRILLIO is a therapeutic adherence device really similar to an “alarm clock”, thus really familiar for elderly. The TRILLIO device is provided with an app that optimizes the connections among various players and organizations who share a common goal: make sure a patient follows his or her pharmaceutical treatment plan. At the centre of this ecosystem is the user, often a senior, surrounded by various stakeholders, all of whom play a key role in the patient's well-being, i.e. family members and caregivers. When it's time to take a drug, TRILLIO alerts the user with a sound and a visual alarm, while showing all the relevant information on its 2.7"" e-paper display. If the user doesn't press the button on the device to turn off the alarm within ten minutes, TRILLIO automatically sends a notification to any family member connected to the system. TRILLIO has been already tested in Italy and received several endorsement and letter of intents by organisations in Italy and abroad.
We are a targeting and overall population composed by 150.000.000 European that are suffering from Chronic diseases, 50% of them have difficulties in following a therapy.
TRILLIO wants to contribute in easing the communication among all the actors of patients ecosystem, enclosing, the patients itself, the family members and the caregivers. The expected output is to contribute to the improvement of adherence to medical plans and medication at European level.

"

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

The feasibility study was carried out in the period 1st may 2018 > 31st October 2018. Main tasks carried out during the period were:
1. Analysis and review on state of the art research papers
2. Analysis on market data
3. Analysis on competitors
4. Analysis of data coming from two pilot projects launched during the feasibility period
5. Analysis of feedback from targeted users
6. P&L account analysis
Main results:
• Validation of Trillio value proposition
• Definition of technology pipeline
• Finalization of P&L account
Dissemination of results
• The project was properly disseminated through
• Project web site
• Participation to trade fairs and conferences
• F2F meetings with stakeholders
Main conclusions
La Comanda defined the proper actions for technology evolution, market strategy and organizational changes.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Trillio is expected to produce important results in increasing therapeutic adherence on elderly or in patients suffering chronic diseases. The pilot results were really encouraging and showed a strong increase in therapies adherence when using Trillio.
Demographic ageing is a global trend. In the European Union (EU), the number of people aged 65+ will almost double over the next 50 years, from 85 million in 2008 to 151 million in 2060. Older people represent a large proportion of the population affected by chronic diseases or multiple chronic diseases. Therefore, in order to adapt and get ready to respond to the needs of these new patients, European healthcare systems’ design has to be revisited and redefined. There is a need to identify and share best practices, mainly in the area of patients self empowerment: IT tools, sharing of common practices need to be identified, replicated and scaled up at EU level.
TRILLIO will contribute in filling these gaps, by providing a solution that has been specifically designed for elderly people and that ease the communication among all the actors of patients ecosystem, enclosing, the patients itself, the family members and the caregivers.
We believe that, at the end of PH2 innovation project, we may bring important social impacts, by improving the life of families, when an elderly person need more support to follow a therapy. We also expect to product important results in terms of lowering the social cost coming from low therapeutic adherence.

Trillio device